We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+8.7%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$187M
AUM Growth
+$19M
Cap. Flow
+$15.2M
Cap. Flow %
8.16%
Top 10 Hldgs %
49.27%
Holding
34
New
9
Increased
10
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$9.05M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.51M
3
RVMD icon
Revolution Medicines
RVMD
+$7.12M
4
ELVN icon
Enliven Therapeutics
ELVN
+$5.44M
5
CLYM
Climb Bio
CLYM
+$5.16M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$11.7M
2
LEGN icon
Legend Biotech
LEGN
+$8.64M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$7.39M
4
GERN icon
Geron
GERN
+$6.39M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$6.05M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVI icon
26
Trevi Therapeutics
TRVI
$2.49B
$4.42M 2.37%
1,322,800
-152,126
-10% -$452K
PRAX icon
27
Praxis Precision Medicines
PRAX
$9.07B
$4.21M 2.25%
73,185
-80,194
-52% -$4.33M
CNTX icon
28
Context Therapeutics
CNTX
$56.4M
$3.44M 1.84%
1,757,524
-128,708
-7% -$286K
PMN icon
29
ProMIS Neurosciences
PMN
$109M
$1.99M 1.07%
63,704
+21,321
+50% +$796K
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-430,245
Closed -$6.05M
BDTX icon
31
Black Diamond Therapeutics
BDTX
$101M
– –
-835,000
Closed -$3.89M
DAWN
32
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-536,095
Closed -$7.39M
LEGN icon
33
Legend Biotech
LEGN
$4.3B
– –
-195,000
Closed -$8.64M
SLNO
34
DELISTED
Soleno Therapeutics
SLNO
– –
-286,162
Closed -$11.7M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q3 2024 Portfolio in Review

As of Q3 2024, Ally Bridge Group held 34 positions worth $187M, up 11% from $168M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Ally Bridge Group deployed $15.2M of net new capital in Q3 2024, opening 9 new positions and adding to 10 existing holdings. Its largest new stake was Tarsus Pharmaceuticals: 321,898 shares worth $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Geron, an estimated $6.39M trimmed.

  • Ally Bridge Group's largest Q3 2024 buy was Tarsus Pharmaceuticals: 321,898 shares worth $10.6M.
  • Ally Bridge Group added most to Climb Bio in Q3 2024, an estimated $5.16M increase.
  • Ally Bridge Group's biggest Q3 2024 reduction was Geron, cutting an estimated $6.39M.
  • Ally Bridge Group fully exited Soleno Therapeutics in Q3 2024, selling an estimated $11.7M.
  • Ally Bridge Group's ten largest holdings make up 49% of its $187M portfolio in Q3 2024.
  • Ally Bridge Group opened 9 new positions and closed 5 in Q3 2024.
  • Ally Bridge Group's portfolio value rose 11% quarter-over-quarter to $187M.

Based on Ally Bridge Group's 13F filing for Q3 2024, filed 14 Nov 2024.